Greencape Capital’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Greencape Capital’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-217,078	Closed	-$4.28M	–	6
2019 Q4	$4.28M	Sell	217,078 -53,202	-20%	-$851K	1.65%	6
2019 Q3	$3.5M	Hold	270,280	–	–	1.24%	6
2019 Q2	$3.37M	Buy	+270,280	New	+$3.59M	1.19%	7

Other funds holding MNTA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Greencape Capital's MNTA Position: Q1 2020 in Review

Greencape Capital sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2020, closing a stake of 217,078 shares — an estimated $4.28M sold.

Greencape Capital first reported a position in MNTA in Q2 2019 and held it in 3 quarters. The position peaked at $4.28M in Q4 2019. 199 funds tracked by Wall St. Rank hold MNTA as of Q1 2020.

Greencape Capital reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Greencape Capital sold 217,078 Momenta Pharmaceuticals, Inc. shares in Q1 2020, an estimated $4.28M.
Greencape Capital first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2019 and held it in 3 quarters.
Greencape Capital's Momenta Pharmaceuticals, Inc. position peaked at $4.28M in Q4 2019.
199 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2020.

Based on Greencape Capital's 13F filing for Q1 2020, filed 15 May 2020.